联系我们
  • 手机:13761418683
    联系人:爱必信
    网址:http://www.absin.cn/
    地   址:上海市浦东新区新浩路58号18号楼
公司动态

前沿科研解读:工程化益生菌攻克结肠炎治疗瓶颈,ELISA 试剂盒助力炎症作用机制深度解析

2026-07-29

近年来,炎症性肠病(IBD)发病率持续攀升,传统治疗手段存在局限性,合成工程益生菌凭借靶向调控肠道菌群、调节肠道免疫的优势,成为肠道炎症治疗的明星研究方向。近期发表于《Cellular & Molecular Immunology》的重磅研究,成功构建了一株定植能力更强、抗炎效果优异的工程化大肠杆菌Nissle 1917(EcN-CPM),系统阐明了其缓解结肠炎的完整分子机制。Absin多款炎症因子ELISA试剂盒在本研究中承担核心检测工作,为实验数据的精准输出、机制论证提供了坚实保障。本文将从研究思路、核心成果、实验工具应用三大维度,带大家深度解析这篇高分文献。

文献标题:Construction of an engineered Escherichia coli strain with enhanced intestinal colonization and anti-inflammatory efficacy in colitis

发表期刊:Cellular & Molecular Immunology(IF 19.8) | DOI:https://doi.org/10.1038/s41423-026-01415-w

使用 Absin 产品:Mouse IL-1β ELISA Kit(abs520001)、Mouse CXCL1/KC (IL-8) ELISA Kit(abs520017)

一、研究背景与整体研究思路

1. 研究痛点

大肠杆菌Nissle 1917(EcN)是应用广泛的安全益生菌底盘菌株,遗传操作体系成熟,可用于改造治疗肿瘤、结肠炎、神经类疾病等多种病症。但天然EcN肠道定植能力弱,难以耐受胃酸、胆汁盐的胁迫,且肠道黏附效果差,极大限制了其作为合成益生菌的临床转化潜力。

过往单一改造耐酸/耐胆盐能力的策略,无法应对胃肠道多重胁迫;包埋等物理改良手段又存在耗材不可再生、操作繁琐等问题。因此,本研究确立多功能基因编辑联合改造的核心思路,从“抗胁迫、强黏附、稳定植”三个维度定向改造EcN,同时结合动物模型、微生物组学、代谢组学、免疫检测等多技术联用,验证工程菌株的抗炎功效与作用机制。

2. 完整研究技术路线

1. 菌株分步改造:通过CRISPR-Cas9基因编辑,分模块优化EcN性能

  • 过表达PatE(耐酸激活因子)+ MdtM(胆盐外排转运蛋白),提升菌株胃酸、胆汁盐耐受能力;
  • 替换curli纤维(卷曲纤维)操纵子强启动子、敲除csgD,增强胞外卷曲纤维合成,强化肠道上皮黏附能力;
  • 整合双模块基因元件,最终获得多功能工程菌株EcN-CPM

2. 体外性能验证:依次检测菌株耐酸、耐胆盐、细胞黏附能力、生长活性。

3. 体内定植验证:利用荧光/荧光素酶标记菌株,在小鼠体内追踪肠道定植时长与定植量。

4. 结肠炎动物药效评价:构建DSS诱导小鼠结肠炎模型,从体征、肠道组织、肠道屏障、炎症水平评估药效。

5. 机制深度解析:16S rRNA测序分析肠道菌群变化、靶向/非靶向代谢组学检测粪便代谢物、检测肠道免疫相关基因与炎症因子表达,串联“菌群-代谢-免疫”调控通路。

6. 生物安全性评价:长期灌胃菌株,检测小鼠血常规、肝肾功能、行为学、脏器系数等,验证菌株临床应用安全性。

二、核心研究成果

本研究层层递进,从菌株改造到机制解析,取得四大突破性成果,完整揭示EcN-CPM缓解结肠炎的作用逻辑。

成果1:成功构建高抗逆、强定植的工程菌株EcN-CPM

天然EcN在胃酸(pH 2.5)、高浓度胆盐环境中存活率极低,且肠道黏附能力不足。本研究通过双基因组合改造实现性能飞跃:

  • 耐酸耐胆盐能力显著提升:过表达PatE可激活大肠杆菌AR1-5全套耐酸系统,大幅提升极端酸性环境下存活率;MdtM可高效转运胆酸盐与脱氧胆酸盐,相比另一转运蛋白DinF作用更广。双基因共表达菌株在模拟胃肠道环境中,90分钟存活率远高于野生型菌株。
  • 肠道黏附能力翻倍:替换curli纤维启动子并敲除调控基因csgD后,菌株卷曲纤维合成量显著增加,对小鼠结肠MC38细胞的黏附能力提升约2倍。
  • 体内定植能力全面领先:整合两大改造模块的EcN-CPM生长活性不受影响;活体成像、粪便菌落计数结果证实,小鼠灌胃后,EcN-CPM在肠道内定植时长、定植数量均远超野生EcN,可在肠道稳定定植5天以上。

Fig. 4 Construction of an engineered EcN strain with high intestinal colonization ability. A Schematic illustration of the construction of the EcN-CPM and EcN-PM. B qRT?PCR analysis of the expression of patE, mdtM, csgE, csgB, and csgD in EcN and EcN-CPM. C Growth curves of EcN, EcN-PM, EcN-Csg, and EcN-CPM. D Electron microscopy-based observation of curli fibers in the EcN, EcN-PM, EcN-Csg, and EcN-CPM (scale bar = 1 μm). E Normalized amyloid production of the EcN, EcN-PM, EcN-Csg, and EcN-CPM groups. F Comparison of the adhesion ability of the EcN, EcN-PM, EcN-Csg, and EcN-CPM groups to MC38 cells. The data are presented as the mean ± SEM. The statistical significance between the two groups was analyzed using a t-test. Statistical comparisons among groups (more than or equal to three groups) were performed using one-way analysis of variance (ANOVA) (*p < 0.05, **p < 0.01, ***p < 0.001)

成果2:EcN-CPM显著缓解DSS诱导的小鼠结肠炎,保护肠道屏障

在DSS结肠炎模型中,相比空白组、野生EcN处理组,EcN-CPM治疗组展现出优异的抗炎表型

  • 小鼠体重下降幅度显著减少,盲肠、结肠长度恢复正常;
  • 结肠组织HE染色显示,肠道上皮结构完整、隐泡排列规则,组织病理评分大幅降低;
  • FITC-葡聚糖实验证明,EcN-CPM可修复受损肠道屏障,降低肠道通透性;
  • 核心炎症因子水平得到精准调控:结肠组织中IL-1β、CXCL1、TNF-α、IL-6、IL-17A、IFN-γ等促炎因子大幅下调,抗炎因子IL-10显著回升,恢复至健康小鼠水平。
Fig. 6 Therapeutic efficacy of EcN-CPM against DSS-induced colitis. A Schematic illustration of the animal experiment. B Changes in body weight and weight change of the mice. C The photographs depict representative cecal and colonic specimens collected from mice on day 10. The lengths of the colon (D) and cecum (E) in the different groups. F HE staining analysis of colon tissues collected from the mice in different groups on day 10. These HE-stained images are representative cross-sections of colon tissues. Scale bars represent 100 μm (main images) and 20 μm (high-magnification views). G Comparative analysis of histopathological scores in colon tissues among the four groups of mice. H Serum concentrations of FITC-dextran in different groups. I Concentrations of seven cytokine markers in the colon tissues of different groups. The data are presented as the mean ± SEM. Statistical comparisons among groups (more than or equal to three groups) were performed using one-way analysis of variance (ANOVA) (*p < 0.05, **p < 0.01, ***p < 0.001)

成果3:重塑肠道菌群结构,驱动有益菌群增殖

16S rRNA测序结果证实,EcN-CPM可逆转结肠炎引发的肠道菌群紊乱:

  • 显著降低致病菌Escherichia-Shigella(志贺菌属)丰度,该菌会破坏肠道屏障、加剧炎症反应;
  • 显著富集norank_f_Muribaculaceae(穆里杆菌科),这类菌群是肠道核心有益菌,可合成短链脂肪酸(SCFAs);
  • 菌群差异与结肠炎表型关联分析表明,菌群结构的改变与炎症缓解、肠道修复高度相关。

Fig. 7 EcN-CPM administration affects the abundance of cecal and colonic microbial genera and their correlations with colitis-associated phenotypes. Relative and inferred absolute abundances of the cecal (A) and colonic (B) microbiomes at the genus level. C Correlations between the cecal and colonic microbes and colitis-associated phenotypes. The association between the colitis phenotype and microbes was determined by Spearman’s rank correlation. The data are presented as the mean ± SEM. Statistical comparisons among groups (more than or equal to three groups) were performed using one-way analysis of variance (ANOVA) (*p < 0.05, **p < 0.01)

成果4:解析“菌群-代谢-免疫”三重抗炎机制

本研究串联代谢组与免疫检测,完整阐明EcN-CPM的抗炎通路,也是全文最核心的机制亮点:

  • 促进短链脂肪酸(SCFAs)恢复:EcN-CPM上清液可直接促进norank_f_Muribaculaceae增殖,逆转DSS诱导的SCFAs耗竭;SCFAs含量与志贺菌属负相关、与穆里杆菌科正相关。
  • 调控Th17/Treg免疫平衡:SCFAs是调控肠道Th17/Treg稳态的关键代谢物。EcN-CPM处理后,结肠组织中Treg细胞标志物(Foxp3、Ctla4、Cd25)表达上调,Th17细胞相关基因(IL-17A、Roryt)表达下调,失衡的IL-17A/Foxp3比值恢复稳态,从细胞层面抑制过度炎症。
  • 恢复7种抗炎代谢物:非靶向代谢组学发现,EcN-CPM可特异性恢复DSS处理后耗竭的马尿酸、松萝酸等7种经典抗炎代谢物,多途径协同抑制肠道炎症。

Fig. 8 EcN-CPM alleviates inflammation by remodeling the gut microbiota and enhancing the levels of fecal metabolites to shift Th17/Treg transcriptional signatures. A Schematic of the experiment assessing the effects of EcN and EcN-CPM supernatants on the relative abundance of norank_f_Muribaculaceae in the fecal microbiota. B The relative abundance of norank_f_Muribaculaceae in groups treated with EcN or EcNCPM supernatants compared with the LB-treated control (Con). C EcN-CPM administration reversed the DSS-induced reduction in the abundance of six short-chain fatty acids (SCFAs). D Correlation analysis between the abundance of the six SCFAs and the relative abundance of Escherichia-Shigella and norank_f_Muribaculaceae. E mRNA expression levels of Foxp3, Ctla4, and Cd25 in colon tissues from the four groups of mice. F Expression levels of IL-17A and Roryt mRNA in colon tissues from the four groups of mice. G The IL-17A/Foxp3 ratio in the colons of the four groups of mice. H Venn diagrams of fecal metabolites identified via nontargeted metabolomics across the four experimental groups. I Principal component analysis (PCA) of gut metabolite profiles among the four groups of mice. J EcN-CPM administration increased the abundance of seven fecal metabolites that were reduced in the DSS group, as determined by nontargeted metabolomics analysis. K Schematic of the mechanism by which EcN-CPM alleviates inflammation through gut microbiome remodeling, which enhances the production of functional fecal metabolites to shift Th17/Treg transcriptional signatures. The data are presented as the mean ± SEM. Statistical comparisons among groups (more than or equal to three groups) were performed using one-way analysis of variance (ANOVA) (*p < 0.05, **p < 0.01, ***p < 0.001)

成果5:EcN-CPM具备良好生物安全性

为期30天的长期灌胃实验证实,EcN-CPM不会影响小鼠体重、进食饮水、神经行为;血常规、肝肾功能、脏器系数均无异常,无明显毒副作用,具备临床转化的安全基础。

三、Absin产品应用详解

在本研究结肠炎药效评价、免疫机制验证的关键环节,研究人员采用Absin品牌ELISA试剂盒完成小鼠结肠组织中多种炎症因子的定量检测,该部分对应原文图6I(7种细胞因子含量检测),是判断菌株抗炎效果、支撑免疫机制结论的核心实验工具

Fig. 6 Therapeutic efficacy of EcN-CPM against DSS-induced colitis.  I Concentrations of seven cytokine markers in the colon tissues of different groups. The data are presented as the mean ± SEM. Statistical comparisons among groups (more than or equal to three groups) were performed using one-way analysis of variance (ANOVA) (*p < 0.05, **p < 0.01, ***p < 0.001)

1. 文中使用的Absin产品清单及对应检测指标

检测指标 Absin产品名称 & 货号 实验作用
IL-1β(白介素-1β) Mouse IL-1β ELISA Kit(abs520001) 检测结肠组织促炎因子水平,评估肠道急性炎症程度
TNF-α(肿瘤坏死因子-α) Mouse TNF-α ELISA Kit(abs520017) 核心促炎因子,量化肠道炎症损伤程度

2. Absin ELISA试剂盒在本研究中的核心作用

精准量化炎症水平,支撑药效结论
DSS诱导结肠炎后,肠道会爆发剧烈炎症,促炎因子大量分泌,抗炎因子表达被抑制。研究人员利用Absin ELISA试剂盒对各组小鼠结肠组织匀浆进行定量检测,直观证明EcN-CPM可显著下调促炎因子、改善肠道炎症状态,为工程菌株缓解结肠炎的药效结论提供直接生化数据支撑。

串联免疫通路,完善机制逻辑
肠道炎症与Th17/Treg免疫失衡密切相关,细胞因子是该通路的核心标志物。Absin ELISA试剂盒精准完成因子定量检测,结合qRT-PCR基因表达结果,印证了EcN-CPM通过调节肠道免疫稳态抑制炎症的分子机制,让菌群、代谢、免疫三大研究模块形成完整逻辑闭环。

适配复杂样本,保障实验稳定性
本实验检测样本为小鼠结肠组织匀浆,基质复杂、干扰成分多。Absin ELISA试剂盒采用成熟双抗体夹心技术,具备高特异性、高灵敏度、低非特异性结合的特点,可有效规避组织样本带来的干扰,检测结果重复性佳、数据误差小,完全满足高分期刊对实验数据严谨性的要求。

3. 产品核心优势

  • 物种高度匹配:全系小鼠炎症因子ELISA试剂盒,针对小鼠样本优化体系,完美适配结肠炎、肠道菌群、免疫调控类动物实验;
  • 检测灵敏度优异:可精准识别组织、细胞上清、血清等样本中的低丰度细胞因子,有效捕捉炎症早期的微弱表达变化;
  • 操作简单高效:预包被板式设计,简化实验流程、缩短操作时长,适合大批量动物样本的批量筛查;
  • 数据认可度高:检测结果可与病理切片、qRT-PCR等主流实验结果相互佐证,已被多篇高分SCI期刊引用。

本文内容基于《Cellular & Molecular Immunology》(DOI: 10.1038/s41423-026-01415-w)原文献;文中涉及的原文献图片、数据等知识产权归原期刊及研究团队所有。若存在侵权情形,敬请及时联系我方删除,我方将积极配合处理。

联系方式
手机:13761418683